Noxopharm Limited

Noxopharm Limited

NOXOF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$13.15M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Noxopharm LimitedNoxopharm Limited-2.4-256%--1.3
$-0.04

Current Fair Value

194.4% downside

Overvalued by 194.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$13.15 Million
Enterprise Value$17.43 Million
Earnings per Share$-0.01
Beta0.14
Outstanding Shares292,237,950

Return

Return on Equity256.04%ROE
Return on Assets-508.44%
Return on Invested Capital282.30%

Valuation & Multiples

P/E Ratio-2.42P/E Ratio
PEG8.53PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.05Price to Book Ratio
Enterprise Value to Revenue6.18
Enterprise Value to EBIT-1.7
Enterprise Value to Net Income-2
Total Debt to Enterprise0.26
Debt to Equity-1.25Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Noxopharm Limited

8 employees
CEO: Olivier Laczka

Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvan...